Actualités et Activités de Syndax Pharmaceuticals
Présence
Syndax Pharmaceuticals fait partie des...
Syndax Pharmaceuticals est une société cotée sous le symbole boursier SNDX (US).
Dirigeants
Voir l'organigramme avec ses 16 principaux dirigeants
Biographies les plus recherchées chez Syndax Pharmaceuticals
- Michael Metzger, Director and Chief Executive Officer
- Jennifer Jarrett, Director
- Pierre Legault, Director
Changements de dirigeants chez Syndax Pharmaceuticals
- Catherine Madigan, Chief Medical Officer, quittera l'entreprise le 31 déc. 2024 (publié le 29 décembre 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Syndax Pharmaceuticals.
Pharmacie
Syndax Pharmaceuticals a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Syndax Pharmaceuticals
- Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
- Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
- Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Syndax Pharmaceuticals
- Syndax Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Syndax Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
